Hørsholm, Denmark (April 22nd, 2020) – Oncology Venture A/S (“OV” or the Company) today announced that it has entered into an agreement with the Pathogen and Microbiome Institute at Northern Arizona University (NAU) to test the antiviral activity of 2X-121, its PARP inhibitor, against Coronavirus.Continue reading
Category Archives: AZBio News
Caris Life Sciences Launches Whole Exome Sequencing with MI Exome
The most comprehensive suite of molecular testing in the industry includes a new whole exome sequencing (DNA) assay complementing the Company’s breakthrough whole transcriptome sequencing (RNA) performed on every patient Continue reading
Novel coronavirus detected, monitored in wastewater
Within weeks of arriving on the world stage, SARS-CoV-2 has managed to encircle the globe, leaving illness, mortality and economic devastation in its vast wake. One of the central challenges facing health authorities and the medical community has been testing for the elusive virus on a sufficiently comprehensive scale.
A new approach to monitoring the novel coronavirus, (as well as other dangerous pathogens and chemical agents), is being developed and refined. Known as wastewater-based epidemiology (WBE), the method mines sewage samples for vital clues about human health. It can potentially identify levels of coronavirus infection at both a local and global scale.Continue reading
LabCorp COVID-19 At-Home Test Kit Receives FDA Emergency Use Authorization
Initial Distribution Prioritized for Frontline Healthcare Workers and First Responders
Quest Diagnostics Begins to Perform COVID-19 Antibody Testing
SECAUCUS, N.J., April 21, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has begun to perform antibody testing for coronavirus (COVID-19) using blood samples. With the new service, Quest Diagnostics now provides healthcare providers in the United States access to COVID-19 antibody as well as molecular diagnostic laboratory testing. Continue reading
C-Path Awarded FDA Contract to Enhance the Assessment of Clinical Outcomes in Pediatric Asthma Treatment Trials
Resulting novel drug development tools will support patient-focused drug development for children with asthma
TUCSON, Ariz., April 21, 2020 — The Critical Path Institute (C-Path) announced today it has been awarded a U.S. Food and Drug Administration (FDA) contract in support of ongoing development of novel clinical outcome assessments for pediatric asthma. C-Path’s Patient-Reported Outcome (PRO) Consortium will carry out this work through its Pediatric Asthma Working Group. Specifically, these assessments are intended to facilitate innovative patient-focused drug development and aid regulatory decision making by filling an unmet measurement gap.Continue reading
Banner Health expands telehealth for COVID-19
Virtual visits provide instant access to medical providers in safe environmentContinue reading
GenoSensor Granted FDA Emergency Use Authorization for High Throughput COVID-19 RT-PCR Diagnostic for Use in U.S.
- FDA Emergency Use Authorization for the GSTM COVID-19 RT-PCR KIT was issued on April 16, 2020. View FDA Letter: https://www.fda.gov/media/137090/download
- With a high sensitivity detection (single copy detection) when run according to its instructions for use in a qualified clinical lab, the GSTM COVID-19 RT-PCR test, is one of the most sensitive tests currently available under an FDA Emergency Use Authorization.
- GSTM COVID-19 RT-PCR KIT runs on the Applied Biosystems™ 7500 Fast Dx Real-Time PCR Instrument. Kits are available for the 96 well plate (22 clinical samples) and 384 well plate (94 clinical samples) and provides test results in less than 90 minutes.
- The GSTM COVID-19 RT-PCR KIT is intended for use by trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. Instructions for use, the FDA EUA letter, and other documentation is provided at GenoSensorCorp.com.
UArizona Launches Two-Way Texting System to Gather and Provide Critical COVID-19 Health Data
TUCSON, Ariz. – Designed to address a critical lack of local data as the COVID-19 pandemic continues to spread, a University of Arizona team of researchers from UArizona Health Sciences and the Data Science Institute is launching a two-way texting system to gather and provide valuable information to track the COVID-19 pandemic in Arizona and identify areas where more resources may be needed.